Suraksha Diagnostic IPO
- IPO Date29 Nov, 2024 to 03 Dec, 2024
- Listing Date06 Jan, 2025
- Face Value₹2 per share
- Issue Price₹420 to ₹441 per share
- Lot Size34 Shares
- Minimum Investment₹14,994
- Listing AtBSE, NSE
- Total Issue Size1,91,89,330 Shares
(aggregating up to ₹846.25 Cr) - Fresh Issue-
- Offer for Sale1,91,89,330 Shares
(aggregating up to ₹846.25 Cr) - Issue TypeBook Built Issue IPO
- Share holding pre issue5,20,80,758
- Shareholding post issue-
IPO Dates
Closing Date
03 Dec, 2024
Initiation of Refunds
05 Dec, 2024
Listing Date
06 Dec, 2024
29 Nov, 2024
Opening Date
04 Dec, 2024
Basis of Allotment
05 Dec, 2024
Credit of Shares
Suraksha Diagnostic Lot Size
Investors can bid for a minimum of 34 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 34 | ₹14,994 |
| B-HNI (Min) | 67 | 2278 | ₹10,04,598 |
| S-HNI (Max) | 66 | 2244 | ₹9,89,604 |
| S-HNI (Min) | 14 | 476 | ₹2,09,916 |
| Retail (Max) | 13 | 442 | ₹1,94,922 |
Suraksha Diagnostic Promoter Holding
The promoters of the company are Dr. Somnath Chatterjee, Ritu Mittal and Satish Kumar Verma.
| Pre Issue Share Holding | Post Issue Share Holding |
|---|---|
| 61.07% | - |
Suraksha Diagnostic COMPANY INFORMATION
Suraksha Diagnostic IPO is a book built issue of Rs 846.25 crores. The issue is entirely an offer for sale of 1.92 crore shares. Suraksha Diagnostic IPO opens for subscription on November 29, 2024 and closes on December 3, 2024. The allotment for the Suraksha Diagnostic IPO is expected to be finalized on Wednesday, December 4, 2024. Suraksha Diagnostic IPO will list on BSE, NSE with tentative listing date fixed as Friday, December 6, 2024. Suraksha Diagnostic IPO price band is set at ₹420 to ₹441 per share. The minimum lot size for an application is 34 Shares. The minimum amount of investment required by retail investors is ₹14,994. The minimum lot size investment for sNII is 14 lots (476 shares), amounting to ₹209,916, and for bNII, it is 67 lots (2,278 shares), amounting to ₹1,004,598. ICICI Securities Limited, Nuvama Wealth Management Limited and SBI Capital Markets Limited are the book running lead managers of the Suraksha Diagnostic IPO, while Kfin Technologies Limited is the registrar for the issue. Refer to Suraksha Diagnostic IPO RHP for detailed information.
Incorporated in 2005, Suraksha Diagnostic offers pathology, radiology testing and medical consultancy services. The company has a central reference laboratory with 8 satellite laboratories and 215 customer touchpoints, including 49 diagnostic centres and 166 sample collection centres as of June 30, 2024, across West Bengal, Bihar, Assam, and Meghalaya.
The company offers its customers online and offline medical consultation services under one roof via 44 diagnostic centres, which house 120 polyclinics with more than 750 doctors.
The operation of the diagnostic centres is supported by the technology platforms and systems that the company uses to streamline, such as its Laboratory Information Management System ("LIMS"), its fully integrated Radiology Information System ("RIS"), its Picture Archive Communication System ("PACS") and its Enterprise Resource Planning System ("ERP").
The company offers vaccination services and customized testing packages for disease prediction/early detection. The company uses digital pathology and artificial intelligence to generate blood tests. All radiology reporting is done through a digital platform that allows cases to be reported from all diagnostic centres, significantly reducing turnaround time.
Competitive Strengths are:
- Well-positioned diagnostics chain to capture the large growth opportunities for organized diagnostics chains in the fragmented markets for diagnostic services in eastern and northeastern India.
- Integrated diagnostics provider offering pathology and radiology testing and medical consultancy services from a single source.
- Well-invested and technologically advanced clinical infrastructure.
- Commitment to quality driving high individual consumer business share and customer retention.
- Management team with relevant industry experience.
Suraksha Diagnostic IPO
IPO Overview and Key Highlights
Suraksha Diagnostic, a leading healthcare and diagnostic services provider, is launching its Initial Public Offering (IPO) comprising a fresh issue of equity shares and an offer for sale. The IPO proceeds aim to fund business expansion, working capital needs, and general corporate purposes. Shares are proposed to be listed on the NSE and BSE.
Key IPO Details
- Type of Issue: Book Built Issue
- Face Value: Rs 2 per share
- Offer Opens: November 29, 2024
- Offer Closes: December 3, 2024
- Listing Exchange: NSE and BSE
Company Overview
Established in 1992, Suraksha Diagnostic is a prominent player in the healthcare diagnostics sector, offering a comprehensive range of diagnostic services, including pathology and radiology. The company has built a strong reputation for quality, innovation, and affordability, catering to patients across India.
Financial Overview
The company has demonstrated consistent revenue growth driven by increasing demand for diagnostic services. IPO proceeds will support capacity expansion, technological upgrades, and operational improvements.
Key Strengths of Suraksha Diagnostic
- Strong Brand Presence: Recognized as a trusted name in diagnostic services.
- Diverse Service Offerings: Comprehensive pathology and radiology services.
- Growth Opportunities: Positioned to benefit from increasing healthcare awareness and diagnostic demand.
IPO Pros and Cons
Pros
- Healthcare Sector Growth: Rising demand for diagnostics amid healthcare reforms and awareness.
- Brand Strength: Established market presence and reputation for reliability.
- Proceeds Utilization: Funds directed toward expansion and improving service offerings.
Cons
- Market Competition: Faces competition from other diagnostic service providers.
- Regulatory Challenges: Subject to evolving healthcare policies and compliance requirements.
- First Public Issue: Uncertainty about stock market performance post-listing.
Risk Factors
Investors should consider:
- Economic Sensitivity: Dependency on patient volumes and healthcare trends.
- Operational Risks: Managing large-scale expansion efficiently.
- Competitive Pressures: Competition from both organized and unorganized sectors.
Conclusion
The Suraksha Diagnostic IPO offers a strong opportunity for investors to participate in the healthcare and diagnostics sector. With its established brand, diverse offerings, and growth-focused strategies, the company is well-positioned for success. However, investors must carefully evaluate risks related to competition and regulatory dependencies before investing.
FAQs About Suraksha Diagnostic Ipo
Suraksha Diagnostic IPO will open on 29 Nov, 2024 and close on 03 Dec, 2024. Investors must apply within this period to participate.
The Suraksha Diagnostic IPO price band is set between ₹420.00 and ₹441.00 per share. The minimum lot size is 34, requiring an investment of at least ₹14994.00.
The Suraksha Diagnostic IPO shares are expected to be listed on 06 Jan, 2025, subject to regulatory approvals and final allotment.
You can track your Suraksha Diagnostic IPO application status on the registrar’s website: Link Intime or KFintech using your PAN, application number, or DP ID
The Suraksha Diagnostic IPO will be listed on major stock exchanges such as NSE and BSE, where you can trade shares once they are listed.